RenovoRx names Mark Voll as chief financial officer
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
RenovoRx Inc (RNXT)
RenovoRx Inc stock price live, this page displays NASDAQ RNXT stock exchange data. View the RNXT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the RenovoRx Inc real time stock price chart below.
What Is the RenovoRx Inc Stock Price Today?
The RenovoRx Inc stock price today is 0.990.
What Is the Stock Symbol for RenovoRx Inc?
The stock symbol for RenovoRx Inc is ""RNXT.""
What Stock Exchange Does RenovoRx Inc Trade On?
RenovoRx Inc is listed and trades on the NASDAQ stock exchange.
Is RenovoRx Inc a Good Stock to Buy?
Determining whether RenovoRx Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNXT quote. (ISIN: US75989R1077)
What Is the RenovoRx Inc Stock Price Today?
The RenovoRx Inc stock price today is 0.990.
What Is the Stock Symbol for RenovoRx Inc?
The stock symbol for RenovoRx Inc is ""RNXT.""
What Stock Exchange Does RenovoRx Inc Trade On?
RenovoRx Inc is listed and trades on the NASDAQ stock exchange.
Is RenovoRx Inc a Good Stock to Buy?
Determining whether RenovoRx Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNXT quote. (ISIN: US75989R1077)
NASDAQ
Currency in USD
Fair Value
An estimate of a RenovoRx's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.950
1.020
52 wk Range
0.701
1.450
RNXT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a RenovoRx's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9501.020
52 wk Range
0.7011.450
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNXT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a RenovoRx's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
6.050
Upside
+511.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Shaun Bagai buys RenovoRx (RNXT) shares worth $4506
- Investing.com
- Form 13G Renovorx For: 30 January
- Investing.com
- RenovoRx names Mark Voll as chief financial officer
- Investing.com
- Form 13G Renovorx For: 30 January
- Investing.com
- RenovoRx receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
RenovoRx Inc Company Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx Inc Earnings Call Summary for Q3/2025
- RenovoRx reported Q3 2025 revenue of $266,000, missing forecasts by 49.63%, while EPS met expectations at -$0.08; stock closed at $1.00, down 2.56%.
- The company expanded its RenovoCath medical device presence from 5 to 14 cancer centers despite revenue challenges, maintaining over $10 million in cash reserves.
- Management projects completing enrollment for Phase III TIGeR-PaC trial by early 2026, with final data expected in 2027 and revenue growth anticipated in 2026.
- Current cash position expected to fund operations into mid-2026, with the company exploring additional financing options including debt/equity and partnerships.
- CEO expressed optimism despite challenges, with 95 patients randomized in the TIGeR-PaC trial toward a target of 114 total randomizations.
Last Updated: 14/11/2025, 00:44
Read Full TranscriptCompare RNXT to Peers and Sector
Metrics to compare | RNXT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNXTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −1.1x | −0.5x | |
PEG Ratio | −0.11 | 0.09 | 0.00 | |
Price/Book | 4.5x | 5.5x | 2.6x | |
Price / LTM Sales | 39.1x | 117.0x | 3.3x | |
Upside (Analyst Target) | 300.0% | 56.2% | 45.7% | |
Fair Value Upside | Unlock | 3.5% | 6.5% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.050
(+511.11% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.08 / -0.08
Revenue / Forecast
200.00K / 397.07K
People Also Watch
FAQ
What Is the RenovoRx (RNXT) Premarket Price Today?
The RenovoRx (RNXT) premarket price is 1.000. Premarket price change units: 0.049. Premarket percentage change: 5.150%. Premarket volume: 7,170.000. Current date: 07 Feb 2026. Previous close: 0.951
What Stock Exchange Does RenovoRx Trade On?
RenovoRx is listed and trades on the Nasdaq Stock Exchange.
TEST
USD
What Is the Stock Symbol for RenovoRx?
The stock symbol for RenovoRx is "RNXT."
What Is the RenovoRx (RNXT) Afterhours Price Today? (Afterhours variable test: 1.020) Current Date: 07 Feb 2026
After hours price: 1.020. After hours price change (units): 0.030. Price change percentage: 3.030%
What Is the RenovoRx Market Cap?
As of today, RenovoRx market cap is 36.28M.
What Is RenovoRx's Earnings Per Share (TTM)?
The RenovoRx EPS (TTM) is -0.34.
When Is the Next RenovoRx Earnings Date?
RenovoRx will release its next earnings report on 31 Mar 2026.
From a Technical Analysis Perspective, Is RNXT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has RenovoRx Stock Split?
RenovoRx has split 0 times.
How Many Employees Does RenovoRx Have?
RenovoRx has 10 employees.
What is the current trading status of RenovoRx (RNXT)?
As of 07 Feb 2026, RenovoRx (RNXT) is trading at a price of 0.990, with a previous close of 0.951. The stock has fluctuated within a day range of 0.950 to 1.020, while its 52-week range spans from 0.701 to 1.450.
What Is RenovoRx (RNXT) Price Target According to Analysts?
The average 12-month price target for RenovoRx is USD6.050, with a high estimate of USD12.5 and a low estimate of USD2.75. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +511.11% Upside potential.
What Is the RNXT Premarket Price?
RNXT's last pre-market stock price is 1.000. The pre-market share volume is 7,170.000, and the stock has decreased by 0.049, or 5.150%.
What Is the RNXT After Hours Price?
RNXT's last after hours stock price is 1.020, the stock has decreased by 0.030, or 3.030%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.